Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Review Panel For Cornerstone’s Lixivaptan To Consider Safety Of Outpatient Initiation

This article was originally published in The Pink Sheet Daily

Executive Summary

The Cardiovascular and Renal Drugs Advisory Committee will face a choice between an agency reviewer’s cautious approach to titration and the sponsor’s push for easier access to the hyponatremia drug.

You may also be interested in...



Cornerstone’s Hyponatremia Therapy Lixivaptan Will Get Advisory Panel Scrutiny

The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters

EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel